Top 83%
en este catálogo (1043 prácticas puntuadas)
Las puntuaciones se concentran en valores altos, por lo que la posición dentro del catálogo suele ser más reveladora que el número por sí solo.
Evidence of impact / measured results2/3
Multiple independent evaluations exist (Manchester Institute 2017, the Connell review 2015, a UKRI-commissioned 2022 study), giving genuine evidence coverage, though the findings themselves are mixed: a positive GBP2.4-per-GBP1 benefit ratio alongside documented weak commercialisation outcomes.
Transferability / demonstrated replication2/3
Modelled on the US SBIR and applied across many UK public bodies (NHS, MOD, DEFRA and others), with the NHS's SBRI Healthcare sub-programme showing the mechanism transfers across sectors.
Scalability1/3
The 2015 Connell review found funding had fallen to GBP63M (a 25% YoY drop) and that roughly 85% of contracts were below the minimum size needed for meaningful benefit, indicating scaling limits.
Sustainability / continuity2/3
Operating in some form since 2001 and still active today as 'Contracts for Innovation' despite a documented mid-2010s funding decline, showing institutional persistence through setbacks.
Innovation1/3
The demand-side, procurement-funded R&D contract mechanism was adapted from the pre-existing US SBIR model rather than newly invented in the UK.
Inclusiveness / equity1/3
Roughly half of applicants are concentrated in southern England per the Cambridge Industrial Innovation Policy group's data, indicating a documented regional imbalance in who benefits.
Multi-stakeholder collaboration2/3
Delivered by Innovate UK/UKRI on behalf of multiple distinct public bodies (NHS, Ministry of Defence, DEFRA and others), reflecting real cross-government coordination, though the 2022 evaluation found departmental ownership still uneven.
Evidoria. SBRI — La Iniciativa Británica de Investigación para Pequeñas Empresas, Revisada y Relanzada Dos Veces. ID persistente: 5c982a46-9285-4b49-9981-ea328752374d.